Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 18 and up

Long-term safety evaluation of NVDX3 treatment

Official title: Long-term Safety Bucket Trial with NVDX3, an Osteogenic Implant of Human Allogenic Origin.

Run by Novadip Biosciences · NCT06532253 · Data updated 2026-11-12

This study is testing the long-term safety of the NVDX3 treatment in patients who have already received it, by checking in with them every year for 10 years to see if they experience any problems.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment15 (estimated)
SponsorNovadip Biosciences
Industry-sponsored
Locations1 site (Luxembourg)
StatusRecruiting
StartedAugust 22, 2024
Main results expectedMarch 2036
Study endsMarch 2036
Registry record updatedSeptember 5, 2024
Trial IDNCT06532253 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients who have previously been treated with NVDX3 and are willing to commit to long-term follow-up.

Probably not a fit

Patients who have not been treated with NVDX3 or those unwilling to participate in long-term follow-up will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the long-term safety of patients who have previously been treated with NVDX3, focusing on those who participated in earlier core clinical trials. Participants will undergo yearly follow-up safety visits for a duration of 10 years to monitor any potential adverse effects or complications associated with the treatment. The study aims to gather comprehensive safety data to ensure the well-being of patients over an extended period.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the long-term safety of NVDX3, enhancing patient confidence in its use.

How similar studies have gone: While this study focuses on long-term safety, similar studies evaluating the safety of treatments have shown success in providing critical data for patient management.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patient being implanted with NVDX3.
2. Previously participated to one of the NVDX3 core clinical trials.
3. Patient accepts to comply to a yearly follow-up safety visit for 10 additional years
4. Patient has understood and accepted to participate in the long-term follow-up study by signing the informed consent.

Exclusion Criteria:

No exclusion criteria are applicable.

Where it's running

  • Centre Hospitalier de Luxembourg
    Luxembourg, Luxembourg
    Recruiting

Study contacts

  • Principal investigator: Torsten Gerich, MD — Centre Hospitalier du Luxembourg
  • Study coordinator: Denis Dufrane, MD
  • Email: clinical@novadip.com
  • Phone: +3210779220

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.